arrow
S

Steven M. Kornblau

md anderson cancer center
H指数:97
被引数:3.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

An all-oral triplet regimen (decitabine/cedazuridine, venetoclax, and gilteritinib) for newly diagnosed and relapsed/refractory FLT3-mutated AML and high-risk MDS

口服三联方案(地西他滨/西达苯胺、维奈克拉和吉列替尼)用于新诊断和复发/难治性FLT3突变急性髓系白血病及高风险骨髓增生异常综合征

2026-10-130
OAAI
Intracellular IL-23R is necessary for mitotic spindle formation and viability in AML

细胞内IL-23R对于AML中的有丝分裂纺锤体形成和存活是必需的

Leukemia
IF13.4
2026-04-170
OAAI
A STAT3 degrader demonstrates efficacy in venetoclax resistant acute myeloid leukemia

STAT3降解剂在Venetoclax耐药急性髓系白血病中显示出疗效

Leukemia
IF13.4
2026-02-170
OAAI
Correction: Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia

更正:维奈克拉联合FLAG-IDA诱导和巩固治疗新诊断及复发或难治性急性髓系白血病的长期结果

Leukemia
IF13.4
2025-12-100
OAAI
A niche driven mechanism determines response and a mutation-independent therapeutic approach for myeloid malignancies

一个利基驱动的机制决定了反应,并提出了一种与突变无关的治疗方法,用于髓系恶性肿瘤。

2025-03-270
PRE
Long-term follow-up of a phase 2 study of all-trans retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin in acute promyelocytic leukemia

全反式维甲酸,三氧化二砷和gemtuzumab ozogamicin在急性早幼粒细胞白血病中的2期研究的长期随访

CANCER
IF5.1
2024-11-251
PRE
A Niche Driven Mechanism Determines Response to ATRA and a Mutation-Independent Therapeutic Approach for MDS and AML

一种小环境驱动机制决定了对ATRA的反应以及一种与突变无关的治疗MDS和AML的方法

BLOOD
IF23.1
2024-11-050
PRE
The Mitochondrial Unfolded Protein Response (UPRmt) Is Upregulated in Acute Myeloid Leukemia (AML) and Inhibiting the UPRmt Protease, LONP1, Leads to Mitochondrial Protein Aggregation and Cell Death Selectively in AML

线粒体未折叠蛋白反应(UPRmt)在急性髓系白血病(AML)中上调,并且抑制UPRmt蛋白酶LONP1会导致线粒体蛋白质聚集,并选择性地在AML中引起细胞死亡。

BLOOD
IF23.1
2024-11-050
PRE
EBFI Activity Controls Leukemia Sensitivity to Inotuzumab Ozogamicin

EBFI活性调控白血病对伊诺妥珠单抗的敏感性

BLOOD
IF23.1
2024-11-050
PRE
Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: a phase 1b/2 clinical trial and correlative analyses

谷氨酰胺酶抑制联合氮杂胞苷治疗骨髓增生异常综合征: 1b/2期临床试验及相关分析

2024-09-190
PRE
Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies LMO2/STAG2 Rearrangements as Extremely High Risk

儿童 γ δ t-all的生物学和临床分析将LMO2/STAG2重排确定为极高风险

2024-06-242
PRE
Investigation of inherited noncoding genetic variation impacting the pharmacogenomics of childhood acute lymphoblastic leukemia treatment
2024-05-011
OAAI
Sotatercept for anemia of myelofibrosis: a phase II investigator-initiated study
2024-04-0411
OAAI
Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia: a phase 2 study
2024-04-016
PRE
Single-cell proteogenomics analysis of AML samples treated with decitabine and venetoclax reveals divergent treatment escape mechanisms
2024-03-220
PRE